ArticleAMB Express2025
Cucurbitacin B alleviates DSS-induced ulcerative colitis by improving gut microbiota disorder in C57BL/6 mice.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cucurbitacin derivatives (B, IIa, IIb, and E): modulating gut dysbiosis and inflammatory pathways for multi-target therapy of ulcerative colitis.Inflammopharmacology · 2026Review
- Article
- EngineeredFrontiers in immunology · 2026Article
- Integrated Multi-Omics, Machine Learning, and Single-Cell Analysis Provide Insights into Potential Multi-Target Candidate Mechanisms of Combined MAGL11 and Icaritin in Alleviating Imidazole Propionate-Driven Metabolic Intestinal Injury.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cucurbitacin B (CuB) is a triterpenoid compound derived from various medicinal plants, demonstrating potential anti-inflammatory, antioxidant, and neuroprotective properties, as well as significant anti-tumor effects. However, its efficacy in treating ulcerative colitis (UC) remains unclear. To investigate the therapeutic potential of CuB, a dextran sulfate sodium (DSS)-induced UC model in mice was employed, along with gut microbiota analysis. The results revealed that CuB significantly alleviated clinical symptoms, improved colonic tissue damage, and suppressed pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in colon tissues. Additionally, CuB was associated with changes in specific microbial populations, including the upregulation of Muribaculaceae, Rikenellaceae_RC9_gut_group, Muribaculum, and Bifidobacterium, and the downregulation of Desulfovibrionaceae, Helicobacter, Escherichia-Shigella, Streptococcus, Candidatus_Saccharimonas, and Clostridium, which may contribute to the recovery of colon injury. This study provides preliminary evidence supporting CuB's therapeutic potential in DSS-induced colitis by enhancing gut microbiota diversity. CuB shows promise as potential treatment for UC and other conditions related to disruptions in intestinal flora homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.